eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Portfolio News / By Karina Tin May 31, 2023
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers Portfolio News / By Karina Tin May 30, 2023
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes Portfolio News / By Karina Tin May 25, 2023
RAPT Therapeutics To Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers Portfolio News / By Karina Tin May 25, 2023
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting Portfolio News / By Karina Tin May 25, 2023
RAPT Therapeutics Reports First Quarter 2023 Financial Results Portfolio News / By Karina Tin May 11, 2023
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Portfolio News / By Karina Tin May 10, 2023
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates Portfolio News / By Karina Tin May 10, 2023
Kallyope Receives $8.2 Million Grant to Identify Novel Interventions for Children and Undernourished Pregnant Women and Mothers Experiencing Environmental Enteric Dysfunction Portfolio News / By Karina Tin May 10, 2023
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin May 9, 2023
